The US-based, independently operated Institute for Clinical and Economic Review (ICER) has established a partnership with the UK’s National Institute for Health Care and Excellence (NICE) and the Canadian Agency for Drugs and Technologies in Health (CADTH), on how to measure value for high-cost gene therapies. What does this mean for the industry? DRG's experts on Global Market Access discuss this collaboration and potential impacts to the industry.
We are part of Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd.
DRG offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1,000 employees across 17 offices in North America, Europe and Asia.Our Company